Key Takeaways
Treat cannabis as a family of medicines, not a universal cure.
A long medical history. People have used cannabis for food, fiber, and medicine for thousands of years. Ancient Chinese medical traditions recorded many uses, and in 1894 a British commission reviewing evidence from India concluded that occasional, moderate use could have medicinal value. That history explains why the plant returned to medical debate, but it does not prove every traditional use works by modern clinical standards.
Useful, not miraculous. Backes frames cannabis as potentially helpful for particular patients and symptoms, while emphasizing that it has side effects and is not right for everyone. He rejects claims that it cures cancer. The guide is intended to inform conversations with physicians, not replace them, and its research picture reflects the book's 2013 publication period.
What's valuable here is the distinction between historical continuity and clinical proof. Long use can identify promising questions and reveal how people have prepared a plant, but it cannot by itself establish benefit, dose, or safety. That distinction protects both patients and the credibility of traditional knowledge. The book's patient-centered stance is especially relevant where people feel dismissed by clinicians, yet openness must not turn into a presumption that a natural product is harmless or effective. In medicine, respect for experience and disciplined testing are partners, not rivals.
Look beyond THC: the body's signaling system shapes cannabis's effects.
A built-in regulatory network. The endocannabinoid system is a network of receptors and naturally produced signaling molecules involved in functions such as pain, appetite, memory, movement, and immune response. The book describes CB1 receptors as concentrated in the brain and linked to many psychoactive effects, while CB2 receptors are more closely associated with immune activity. The system helps regulate communication between cells, rather than serving one isolated function.
Plant compounds meet body chemistry. Cannabis contains more than 700 chemical compounds, including cannabinoids such as THC and CBD. THC interacts with cannabinoid receptors; CBD acts through a broader set of signaling pathways. This biology helps explain why cannabis can affect multiple symptoms, but broad biological activity does not automatically mean proven treatment for every condition.
The endocannabinoid system offers a useful systems-biology lens: one regulatory network can connect symptoms that otherwise seem unrelated, such as appetite, pain, and mood. That perspective helps generate research questions beyond asking whether a single molecule hits a single target. It also cautions against simplistic claims. A widely distributed control system is not a universal therapeutic switch. Changing one part can ripple into others, so the same biological breadth that makes cannabis intriguing also makes careful testing and monitoring essential.
Read chemical profiles, not strain names, to anticipate effects.
Chemistry is the better map. A chemotype is a plant type defined by the combination of chemicals it produces. Cannabis chemotypes differ in cannabinoids, including THC and CBD, and in aromatic compounds called terpenes. Backes argues that these chemical differences help explain why two products with similar THC levels can feel different. He also challenges the familiar indica and sativa labels, which often describe appearance or reported effects poorly and do not reliably identify a product's chemistry.
Interactions may matter. The book presents the entourage effect as the possibility that cannabinoids and terpenes influence one another's effects. For example, it reports that CBD may reduce some THC-related anxiety, while pinene may affect short-term memory effects. These interactions are promising explanations, not a settled formula for predicting an individual's response.
This is a move from branding toward measurable product identity. It resembles food science, where a product's ingredients and processing matter more than a colorful package name. The approach also exposes a challenge: a chemical profile may be more informative than a strain label, but it does not yet translate neatly into a reliable prediction of experience or clinical outcome. Composition is a necessary bridge between product and effect, not the whole bridge. Patient response, route, timing, and context still shape what happens.
Use the smallest helpful dose, because more can work worse.
Dose is individual. Backes recommends seeking the minimum amount that provides the desired symptom relief. The same amount can affect people differently because absorption varies, tolerance changes, and products differ in potency. In the book, oral THC absorption is reported to vary from 4 to 12 percent across patients. That spread makes a fixed dose or a joint-sized unit a poor guide to what someone actually receives.
High doses have costs. The book describes receptor down-regulation, a reduction in available cannabinoid receptors after sustained high exposure. This can contribute to tolerance, meaning that more is needed to produce the same effect. It also discusses pain research in which a middle dose helped more than a higher dose. The practical lesson is cautious titration with professional guidance, rather than treating stronger effects as better treatment.
The dose-response idea is more subtle than the familiar assumption that a stronger dose produces a stronger benefit. Biological systems can respond nonlinearly, and pain itself can worsen when a treatment overshoots its useful range. This makes careful observation part of treatment: record the amount, timing, route, symptom change, and unwanted effects. The book's advice is strongest when read as a principle of controlled experimentation, not as a universal dosing schedule. Individual variability makes clinician involvement especially important.
Choose delivery by timing: inhalation is fast, while edibles last longer.
Routes change the experience. Inhaled cannabis reaches the bloodstream quickly, with peak THC levels typically reported within minutes. That rapid onset can make small adjustments easier. Oral cannabis takes longer and is less predictable because digestion and liver metabolism affect how much reaches circulation. The liver also converts THC into 11-hydroxy-THC, a metabolite the book describes as more psychoactive and longer-lasting than THC itself.
Delayed effects invite mistakes. The book reports that oral effects may begin anywhere from 15 minutes to three hours later and can last five to eight hours. Sublingual products, placed under the tongue or against the mouth lining, can act faster than swallowed products. Each route has tradeoffs: inhalation exposes the lungs to smoke or vapor, while oral products can be difficult to judge before their effects arrive.
Route is not a minor convenience choice; it changes the drug's time course and the user's ability to respond to it. This is a familiar principle in pharmacology, where absorption and metabolism can make the same substance behave differently depending on how it enters the body. Delayed effects are especially easy to misread as no effect, prompting repeat use before the first dose has peaked. Clear labeling and patient education are therefore part of safe formulation, not mere packaging details.
Separate relief of symptoms from claims that cannabis treats disease.
Evidence is not uniform. The book describes the strongest practical rationale in symptom relief, including chemotherapy-related nausea, appetite loss, some chronic pain, neuropathy, and multiple-sclerosis spasticity. It cites a small controlled study of smoked cannabis in people with MS that found reduced spasticity and an average pain reduction of about 50 percent among participants receiving cannabis. Results from other conditions are more limited or inconsistent.
Cancer claims need restraint. Cannabinoids have shown antitumor effects in cell studies and some animal models, but the book says this had not established cannabis as a cancer cure in people. Cancer includes many different diseases, and a promising laboratory result cannot be generalized to all of them. The guide repeatedly distinguishes possible mechanisms and early signals from demonstrated clinical benefit.
The distinction between symptom control and disease modification is a crucial safeguard against false hope. A treatment can meaningfully improve appetite, nausea, pain, or sleep without shrinking a tumor or altering the course of an illness. Those outcomes matter, but they answer different questions. The book's account is most persuasive when evidence is tied to a specific condition and outcome. Its 2013 research landscape should not be mistaken for a current clinical review, so present-day decisions require up-to-date medical sources.
Make side effects and interactions part of the treatment plan.
Not harmless by default. The book lists anxiety, panic, confusion, rapid heartbeat, dizziness, and fainting on standing among possible effects, especially for inexperienced users or after high doses. Smoking can irritate the lungs, and long-term heavy smoking may cause chronic bronchitis. Cannabis may also alter the effects of alcohol, opioids, and benzodiazepines. Oral products can interact with medicines processed by the liver, sometimes increasing or reducing their effects.
Know when caution rises. Backes urges particular care for people with heart conditions, high blood pressure, immune disorders, or serious psychiatric diagnoses. He describes cannabis hyperemesis, a pattern of vomiting and abdominal pain associated with prolonged cannabis use that may resolve after stopping. The book advises medical consultation and notes that pregnancy and breastfeeding are not recommended settings for cannabis use.
A side-effect list becomes useful only when it changes decisions. This section encourages a broader definition of safety: not just whether a substance can cause direct toxicity, but whether it impairs judgment, interacts with another drug, or creates risk during a fall or while driving. That framing is especially important for older patients and people managing several medicines. At the same time, risks differ by dose, route, and person, so generalized warnings should prompt individualized review rather than automatic conclusions.
Treat a strain name as a guess until chemical testing verifies it.
Names outpace standards. The book describes dispensaries offering many varieties with names that often lack consistent definitions. A product sold under the same name may differ across growers or batches, and even sellers may not know its precise ancestry. Modern breeding, cloning, and selection for potency and indoor growth have also narrowed the gene pool, according to Backes, while many older landrace varieties became difficult to find.
Fingerprint the product. Chemical fingerprinting measures the usual cannabinoid and terpene profile of a variety. Genetic fingerprinting examines inherited traits associated with that profile. The book presents these tools as a route toward consistent naming and more useful comparisons. Until that consistency exists, a label such as indica, sativa, or a famous cultivar name should not be treated as a dependable clinical specification.
This is a problem of measurement and governance as much as botany. A name only supports clinical learning if it reliably points to a repeatable product. Without standardization, an apparent success with one batch may not transfer to another bearing the same label, making both patient records and research harder to interpret. Chemical testing can improve reproducibility, but it cannot alone establish which profile works for which person. That requires connecting product data to patient outcomes.
Demand clean, tested products because cultivation errors can harm patients.
Purity is clinical quality. Cannabis can carry pesticide residues, harmful molds, bacteria, or synthetic plant-growth regulators. Some dangerous fungi cannot be identified by sight and require laboratory testing. The book notes that contaminants often result from poor cultivation, drying, or handling rather than deliberate adulteration. Patients with immune disorders may be especially vulnerable to microbial contamination.
Testing must match the risk. A potency test does not necessarily screen for pesticides or pathogens. Backes recommends asking what a laboratory actually tests and whether its methods are independently validated. He also warns that edible products can be inaccurately labeled, making their cannabinoid content hard to judge. Proper storage matters too: heat, light, air, and moisture can degrade delicate compounds or encourage spoilage.
The book's quality-control argument extends beyond cannabis. Any plant-based medicine is shaped by agriculture, processing, storage, and labeling, so its safety cannot be inferred from its natural origin. Independent testing is valuable only when the testing scope is transparent and relevant to the hazard. This is where regulation can protect patients without requiring certainty about every therapeutic claim. A clean product may still be ineffective for a particular condition, but an unclean one introduces avoidable risks before efficacy is even considered.
Recognize how prohibition distorted both research and cannabis breeding.
A medical plant became a political symbol. Cannabis was listed as medicine in the United States Pharmacopeia until 1942, after federal restrictions had sharply limited access. The American Medical Association objected to the 1937 Marihuana Tax Act, warning that research and medical development should not be shut off. The book traces how prohibition then made clinical study difficult and pushed much practical knowledge into informal patient communities.
The AIDS crisis changed the debate. In the 1980s and 1990s, patients with HIV/AIDS used cannabis to address appetite loss, nausea, and treatment side effects. Activists and providers, including San Francisco's Brownie Mary and physician Donald Abrams, helped bring those experiences into public view and research. Meanwhile, illicit cultivation favored compact, fast-flowering, high-THC plants, shaping the varieties available to patients.
The historical thread shows how policy can shape the evidence it later claims to evaluate. When research access is restricted, the record becomes uneven: patient testimony grows while controlled studies lag, and uncertainty can then be used to justify further restriction. This does not make anecdotes equivalent to trials, but it explains why the evidence base developed unevenly. The breeding story is equally revealing: legal pressure did not merely affect access, it influenced which plant traits survived and were selected.
For children, pregnancy, and psychiatric risk, uncertainty demands clinical oversight.
The stakes are not equal for everyone. The book warns that THC may affect the developing brain and may pose added concerns for young people with a susceptibility to psychosis. It describes prenatal and breastfeeding exposure as concerning because cannabinoids interact with systems involved in development. Older, cannabis-naive patients may also experience dizziness or disorientation that they find alarming.
Promising is not proven. Parents reported using CBD-rich products for severe childhood epilepsy, but the book describes this evidence as primarily anecdotal and notes the need for blinded clinical trials. It presents no simple answer for pediatric treatment. Its consistent recommendation is that a physician, parent, and patient weigh possible benefit against uncertainty, existing treatments, dose, and the child's condition.
This is where uncertainty has the highest ethical cost. For a child with severe, treatment-resistant illness, waiting for perfect evidence can also carry harm, while acting on compelling stories can expose a child to unknown risks. The relevant question is not whether hope is rational, but how decisions are governed: transparent evidence, expert supervision, careful outcome tracking, and clear discussion of alternatives. The same caution applies to pregnancy and psychiatric vulnerability, where individual context matters more than a general claim about cannabis.
Analysis
The book's central contribution is not a list of conditions for which cannabis might help. It is a way of seeing cannabis as a variable botanical medicine whose effects depend on chemistry, preparation, route, dose, and patient. That framework is more useful than the familiar argument over whether cannabis is simply good or bad. It also explains why one patient's relief cannot safely be generalized to another product or person.
Its strongest reasoning appears where the author separates levels of evidence. Historical records and patient reports generate hypotheses; laboratory and animal work suggest mechanisms; controlled human studies test specific outcomes. These categories are not interchangeable. The book sometimes moves quickly from a plausible biological mechanism to a proposed medical application, so readers should treat those passages as research leads, not clinical conclusions. The cancer discussion demonstrates the difference particularly well: cell and animal findings are intriguing, but they do not establish a general human cure.
A second strength is its attention to implementation. A medicine's real-world usefulness depends not only on pharmacology but also on whether the product is identifiable, consistently made, accurately labeled, and safely stored. The account of strain names, contamination, and dose variability makes regulation part of medical quality, not a separate political concern. That insight applies to botanical products broadly.
The book is also historically situated. It was published in 2013, when cannabinoid research and access were changing rapidly. Its observations should therefore be read as a record of an evolving field, not as current treatment guidance. Its lasting lesson is methodological: preserve patient experience, demand better measurement, distinguish symptom relief from disease treatment, and let uncertainty lead to careful inquiry rather than either dismissal or hype.
Review Summary
Cannabis Pharmacy by Michael Backes receives overwhelmingly positive reviews for its comprehensive, scientific approach to medical marijuana. Readers praise its detailed information on various strains, medical conditions, and administration methods. Many find it an invaluable resource for understanding cannabis's medicinal properties and potential benefits. The book is lauded for its accessibility to both newcomers and experienced users, providing evidence-based information without hype. Some readers note that certain information may be outdated due to rapid advancements in the field, but overall consider it an essential reference for those interested in medical cannabis.
People Also Read
Glossary
Endocannabinoid system
body-wide signaling networkA network of cannabinoid receptors and naturally produced signaling molecules found throughout the body. It helps regulate processes including pain, appetite, memory, movement, and immune activity. Plant cannabinoids can interact with parts of this system, but the system's broad reach also means that effects may extend beyond the symptom a person hopes to address.
Phytocannabinoid
plant-produced cannabinoidA cannabinoid produced by plants, especially cannabis. THC, CBD, CBG, and CBC are examples discussed in the book. In the plant, many occur in acidic forms that can change into neutral forms through heat or time. The book notes that some non-cannabis plant compounds can also interact with cannabinoid receptors.
Terpenoids
aromatic plant compoundsVolatile compounds found in the essential oils of many plants. They account for much of cannabis's aroma, since cannabinoids themselves have little smell. The book describes terpenoids as pharmacologically active and proposes that they may influence the effects of cannabinoids, although the significance of these interactions requires further research.
Chemotype
distinct chemical profileA plant type distinguished by the combination of chemicals it produces. In cannabis, a chemotype may be characterized by its proportions of cannabinoids, such as THC and CBD, as well as its terpenoids. The term is more useful for comparing potential effects than a strain name alone, though a profile does not guarantee a particular response.
entourage effect
combined compound interactionsThe proposed idea that cannabinoids and terpenoids can modify one another's effects when present together in cannabis. The book offers examples such as CBD potentially reducing some THC-related anxiety. The concept helps explain why whole-plant products may differ from isolated THC, but it remains a research hypothesis rather than a reliable prediction rule.
decarboxylation
heat-activated chemical conversionA chemical process in which an acidic cannabinoid loses a carboxyl group and becomes a neutral form, such as THCA becoming THC. Heat can make this conversion happen quickly, while time and moderate temperatures can contribute more gradually. The change affects how readily the compound can be absorbed and whether THC produces psychoactive effects.
micro-dosing
minimum effective amountA method of using a very small amount of cannabis, near or below the threshold of noticeable psychoactivity, then assessing the result before adjusting. Backes presents it as a way to seek symptom relief while reducing unwanted effects and tolerance. The amount that works varies by person, product, and route, so the term does not specify a universal dose.
first-pass effect
early liver metabolismThe reduction or alteration of a drug before it reaches general circulation, usually because it is metabolized in the liver after being swallowed. The book explains that oral THC can be affected by this process, contributing to variable absorption. The liver also produces 11-hydroxy-THC, a metabolite described as more psychoactive and longer-lasting than THC.
receptor down-regulation
reduced receptor availabilityA decrease in the number or availability of receptors following sustained exposure to a signaling substance. The book links repeated high cannabinoid exposure with reduced CB1 receptor density and the development of tolerance. In practical terms, the same amount may produce less effect over time, while a break from use may allow receptor levels to recover.
Clinical Endocannabinoid Deficiency (CECD)
proposed signaling deficiencyA hypothesis that insufficient endocannabinoid signaling may contribute to some conditions, including migraine, fibromyalgia, and irritable bowel syndrome. The idea suggests that plant cannabinoids could supplement a deficient system. The book presents CECD as a proposed explanation, not an established diagnosis or proof that cannabis treats those disorders.
FAQ
What’s Cannabis Pharmacy: The Practical Guide to Medical Marijuana by Michael Backes about?
- Comprehensive medical cannabis guide: The book offers a detailed overview of cannabis as a medicine, including its history, chemistry, varieties, and therapeutic uses.
- Structured for accessibility: It is organized into four parts, covering everything from the biological basis of cannabis to its practical application for specific conditions.
- Evidence-based and practical: The guide combines scientific research, patient observations, and real-world advice for both patients and healthcare professionals.
- Legal and safety context: It addresses legal, workplace, and safety considerations for medical cannabis users.
Why should I read Cannabis Pharmacy by Michael Backes?
- Bridges knowledge gaps: The book fills the void of accessible, evidence-based information on medical cannabis, helping both patients and doctors make informed decisions.
- Expert insights: Michael Backes synthesizes hundreds of studies and clinical experience, offering practical advice on dosage, storage, and delivery methods.
- Debunks myths: It clarifies misconceptions, such as cannabis being a cure-all or risk-free, and encourages a rational, scientific approach to cannabis medicine.
- Holistic understanding: Readers gain a well-rounded perspective on the endocannabinoid system, cannabinoid chemistry, and the entourage effect.
What are the key takeaways from Cannabis Pharmacy by Michael Backes?
- Cannabis is not a panacea: While useful and relatively safe for many, cannabis is not a cure-all and should be used with realistic expectations.
- Individualized treatment is crucial: The book emphasizes the importance of finding the right strain, dose, and delivery method for each patient.
- Legal and workplace challenges: Navigating the legal landscape and workplace policies is essential for safe and responsible medical cannabis use.
- Scientific foundation: Understanding the endocannabinoid system and the synergy of cannabinoids and terpenes is key to effective therapy.
What are the most notable quotes from Cannabis Pharmacy by Michael Backes and what do they mean?
- On cannabis history: “From the perspective of someone who has studied traditional therapies as a career, it is surprising that cannabis ever left our medicine cabinets...” —Andrew Weil, M.D. This highlights the long medicinal heritage of cannabis and the irony of its prohibition.
- On cannabis as medicine: “Cannabis is certainly not a panacea, but for specific individuals and circumstances, it is very useful and quite safe.” —Michael Backes. This emphasizes realistic expectations and individualized treatment.
- On cannabis chemistry: “It is extraordinary that one plant can produce so many safe, pharmacologically active substances...” —Michael Backes. This underscores the complexity and therapeutic potential of cannabis’s chemical makeup.
How does Cannabis Pharmacy by Michael Backes explain the endocannabinoid system and its role in medical cannabis?
- Body’s regulatory network: The endocannabinoid system (ECS) is a neuromodulatory network that regulates appetite, pain, mood, memory, and immune response.
- Cannabinoid interaction: Plant cannabinoids like THC and CBD interact with the body’s CB1 and CB2 receptors, modulating physiological processes and providing therapeutic effects.
- Target for treatment: Many medical conditions involve ECS dysfunction, making it a promising target for cannabinoid-based therapies.
- Entourage effect: The book highlights the synergy between cannabinoids and terpenes, enhancing therapeutic outcomes beyond isolated compounds.
What are the main medical uses of cannabis according to Cannabis Pharmacy by Michael Backes?
- Symptom relief: Cannabis alleviates pain, nausea, muscle spasticity, anxiety, insomnia, and appetite loss in conditions like cancer, HIV/AIDS, and multiple sclerosis.
- Neuroprotective and anti-inflammatory: Cannabinoids may protect nerve cells and reduce inflammation, benefiting diseases like Alzheimer’s, Parkinson’s, and autoimmune disorders.
- Mental health applications: Cannabis may help with anxiety disorders, PTSD, and some symptoms of schizophrenia, though caution is advised due to psychoactive effects.
- Emerging research: The book discusses promising but preliminary evidence for cannabis use in epilepsy, autism spectrum disorders, and diabetes.
What practical advice does Michael Backes give on dosing and administration methods in Cannabis Pharmacy?
- Start low, go slow: The book recommends starting with low doses (e.g., 2.5 to 5 mg THC) and gradually increasing to find the optimal dose.
- Oral and sublingual: Oral ingestion provides long-lasting effects, while sublingual administration offers faster onset and better dose control.
- Inhalation: Vaporization and smoking allow rapid onset and easy dose titration, preferred for acute symptom relief but with respiratory considerations.
- Topical use: Topical cannabinoid preparations are effective for localized conditions and avoid systemic psychoactivity.
How does Cannabis Pharmacy by Michael Backes describe the differences among cannabis varieties and their medical effects?
- Genetic and chemical diversity: Cannabis varieties differ in cannabinoid and terpene profiles, producing distinct medicinal and psychoactive effects.
- Beyond indica/sativa: The book debunks the simplistic indica/sativa dichotomy, emphasizing chemotype and terpene content for medical selection.
- Landrace and hybrid strains: Traditional landraces and modern hybrids like OG Kush and Blue Dream are profiled for their unique traits and medical uses.
- Variety selection: Patients are advised to consider aroma, taste, cannabinoid ratios, and terpene profiles to select the best variety for their condition.
What are the recommended cannabis strains and their characteristics in Cannabis Pharmacy by Michael Backes?
- S.A.G.E.: Tall, soil-grown, moderate THC (15-18%), sweet sandalwood aroma, stimulating effects, often used for hashish.
- Sensi Star: Indica-dominant, high THC (~20%), strong analgesic and sedative effects, effective for GI disorders and insomnia.
- Skunk #1: Hybrid, high potency (~20% THC), smooth taste, long-lasting effects, historically significant in medical cannabis.
- Sour Diesel, Strawberry Cough, Trainwreck, White Widow: Each has unique cannabinoid/terpene profiles, effects, and medical applications, from mood elevation to neuropathy relief.
How does Cannabis Pharmacy by Michael Backes explain the entourage effect and its importance in medical cannabis therapy?
- Synergistic interaction: The entourage effect is the combined action of cannabinoids and terpenes, producing enhanced therapeutic effects.
- Terpene roles: Terpenes like myrcene, limonene, linalool, and pinene contribute to aroma, flavor, and pharmacological effects such as sedation and analgesia.
- Strain selection: Understanding terpene and cannabinoid profiles helps tailor therapy to specific conditions and patient needs.
- Whole-plant advocacy: The book recommends whole-plant or multi-compound medicines to leverage the entourage effect for better symptom relief and fewer side effects.
What are the main risks and side effects of medical cannabis according to Cannabis Pharmacy by Michael Backes?
- Psychoactivity and tolerance: THC can cause anxiety, dry mouth, red eyes, and cognitive impairment at high doses; tolerance may develop with regular use.
- Cannabinoid hyperemesis syndrome: Rare but severe nausea and vomiting can occur in chronic users, relieved by cessation and hot showers.
- Dependency and withdrawal: Dependence is rare and usually linked to heavy, prolonged use; withdrawal symptoms are mild.
- Special populations: Caution is advised for adolescents, pregnant women, and those with psychiatric disorders, emphasizing professional oversight.
How does Cannabis Pharmacy by Michael Backes address legal and workplace challenges for medical cannabis users?
- Complex legal landscape: Only some U.S. states permit medical cannabis, often with complex regulations and limited access.
- Workplace policies: Many employers have zero-tolerance drug policies, risking job loss for patients even if not impaired at work.
- Driving and safety: Cannabis impairs driving ability, especially when combined with alcohol, and no reliable blood THC level defines impairment.
- Need for informed guidance: Patients may rely on illicit sources, making evidence-based advice and legal awareness essential.
Download PDF
Download EPUB
.epub digital book format is ideal for reading ebooks on phones, tablets, and e-readers.